Yvonne Greenstreet Sells 5,219 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 5,219 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the sale, the chief executive officer now directly owns 78,880 shares in the company, valued at approximately $19,797,302.40. This trade represents a 6.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $0.39 during mid-day trading on Wednesday, hitting $253.74. The company had a trading volume of 718,060 shares, compared to its average volume of 877,936. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The business’s 50-day simple moving average is $272.32 and its 200-day simple moving average is $240.10. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a market cap of $32.73 billion, a P/E ratio of -96.70 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the firm posted $1.15 EPS. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Eventide Asset Management LLC raised its position in Alnylam Pharmaceuticals by 157.9% in the third quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after purchasing an additional 137,333 shares in the last quarter. Los Angeles Capital Management LLC raised its position in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares in the last quarter. AQR Capital Management LLC raised its position in Alnylam Pharmaceuticals by 92.5% in the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after purchasing an additional 130,482 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new position in Alnylam Pharmaceuticals in the second quarter worth about $29,111,000. Finally, Avoro Capital Advisors LLC raised its position in Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock worth $97,200,000 after purchasing an additional 100,000 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of several recent analyst reports. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Raymond James upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.